Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Kratochwil, Clemens [VerfasserIn]   i
 Haberkorn, Uwe [VerfasserIn]   i
Titel:EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
Verf.angabe:Clemens Kratochwil, Wolfgang Peter Fendler, Matthias Eiber, Richard Baum, Murat Fani Bozkurt, Johannes Czernin, Roberto C. Delgado Bolton, Samer Ezziddin, Flavio Forrer, Rodney J. Hicks, Thomas A. Hope, Levant Kabasakal, Mark Konijnenberg, Klaus Kopka, Michael Lassmann, Felix M. Mottaghy, Wim Oyen, Kambiz Rahbar, Heiko Schöder, Irene Virgolini, Hans-Jürgen Wester, Lisa Bodei, Stefano Fanti, Uwe Haberkorn, Ken Herrmann
E-Jahr:2019
Jahr:22 August 2019
Umfang:9 S.
Fussnoten:Gesehen am 03.12.2019 ; Die Zahl "177" ist im Titel hochgestellt
Titel Quelle:Enthalten in: European journal of nuclear medicine and molecular imaging
Ort Quelle:Heidelberg [u.a.] : Springer-Verl., 2002
Jahr Quelle:2019
Band/Heft Quelle:46(2019), 12, Seite 2536-2544
ISSN Quelle:1619-7089
Abstract:Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can be identified by PSMA-ligand imaging, which has already become clinically accepted in several countries in- and outside Europe. PSMA-directed radioligand therapy (PSMA-RLT) with Lutetium-177 (177Lu-PSMA) is currently undergoing clinical validation. Retrospective observational data have documented favourable safety and striking clinical responses. Recent results from a prospective clinical trial (phase II) have been published confirming high response rates, low toxicity and reduction of pain in metastatic castration-resistant prostate cancer (mCRPC) patients who had progressed after conventional treatments. Such patients typically survive for periods less than 1.5 years. This has led some facilities to adopt compassionate or unproven use of this therapy, even in the absence of validation within a randomised-controlled trial. As a result, a consistent body of evidence exists to support efficacy and safety data of this treatment. The purpose of this guideline is to assist nuclear medicine specialists to deliver PSMA-RLT as an “unproven intervention in clinical practice”, in accordance with the best currently available knowledge.
DOI:doi:10.1007/s00259-019-04485-3
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1007/s00259-019-04485-3
 DOI: https://doi.org/10.1007/s00259-019-04485-3
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Lutetium
 Nuclear medicine
 Prostate cancer
 PSMA
 Radionuclide therapy
 Theranostics
K10plus-PPN:1684061547
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68462999   QR-Code
zum Seitenanfang